Zeolite (clinoptilolite) and IBS

What 2 graded rows on zeolite (clinoptilolite) agree on for IBS, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Zeolite (clinoptilolite) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Zeolite (clinoptilolite) page, with its PubMed record.

Supplement

Zeolite (clinoptilolite) Choose another

2 rows · 71 people

Split. 1 row found no difference and 1 had mixed results.

No difference or mixed

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside. Outlined: mixed results.

From the rows

The best-graded row, grade D, is a pilot trial of 41 people (2021) and found no difference.

The rows run from 30 to 41 people, published from 2021 to 2022: 2 single studies.

1 no difference · 1 mixed

Grade DIBS symptoms and gut inflammation markers · No difference
Pilot RCT · n 41 · 2021 · Adults with irritable bowel syndrome
3 g twice a day · 3 months
Symptom scores fell significantly in both groups, which the authors read as a strong placebo effect. Stool alpha-1-antitrypsin fell more with zeolite (p = 0.037) and hsCRP was lower.
Row on the Zeolite (clinoptilolite) page · PubMed 33930939 (opens PubMed)
Grade DIBS with diarrhea symptom relief · Mixed
Pilot RCT · n 30 · 2022 · Adults with IBS-D (Rome IV)
2 g three times a day · 12 weeks
Responders at 12 weeks were 21% vs 25% (primary endpoint not met). At 4 weeks 36% vs 0% reported considerable relief, diarrhea days fell 2.4 vs 0.3 a week, and fewer needed rescue medicine; no serious product-related events.
Row on the Zeolite (clinoptilolite) page · PubMed 36569277 (opens PubMed)